AYTU BIOPHARMA, INC Incremental Common Shares Attributable to Dilutive Effect of Conversion of Preferred Stock
AYTU BIOPHARMA, INC (AYTU) reported Incremental Common Shares Attributable to Dilutive Effect of Conversion of Preferred Stock of 44 shares for the 3-month period ending 2019-09-30, per its 10-Q filed 2019-11-14.
Discontinued › Income Statement › Earnings Per Share
us-gaap:IncrementalCommonSharesAttributableToConversionOfPreferredStock · last filed 2019-11-14
- AYTU BIOPHARMA, INC incremental common shares attributable to dilutive effect of conversion of preferred stock for the quarter ending 2019-09-30 was 44.00 shares.
- AYTU BIOPHARMA, INC incremental common shares attributable to dilutive effect of conversion of preferred stock for the quarter ending 2018-09-30 was 0.00 shares.
| Period end | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Preferred Stock 3 month |
|---|---|
| 2019-09-30 | 44.00 shares 10-Q · filed 2019-11-14 |
| 2018-09-30 | 0.00 shares 10-Q · filed 2019-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |